Please note that the copy function is not enabled for this field.
If you wish to
modify
existing outcomes, please copy and paste the current outcome text into the Update field.
LOGIN
CREATE ACCOUNT
LOGIN
CREATE ACCOUNT
MY TRIALS
REGISTER TRIAL
FAQs
HINTS AND TIPS
DEFINITIONS
Trial Review
The ANZCTR website will be unavailable from 1pm until 3pm (AEDT) on Wednesday the 30th of October for website maintenance. Please be sure to log out of the system in order to avoid any loss of data.
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this
information for consumers
Download to PDF
Trial details imported from ClinicalTrials.gov
For full trial details, please see the original record at
https://clinicaltrials.gov/study/NCT00066703
Registration number
NCT00066703
Ethics application status
Date submitted
6/08/2003
Date registered
7/08/2003
Date last updated
2/01/2024
Titles & IDs
Public title
Triptorelin With Either Exemestane or Tamoxifen in Treating Premenopausal Women With Hormone-Responsive Breast Cancer
Query!
Scientific title
A Phase III Trial Evaluating The Role Of Exemestane Plus GnRH Analogue As Adjuvant Therapy For Premenopausal Women With Endocrine Responsive Breast Cancer
Query!
Secondary ID [1]
0
0
IBCSG 25-02
Query!
Secondary ID [2]
0
0
IBCSG 25-02 / BIG 3-02
Query!
Universal Trial Number (UTN)
Query!
Trial acronym
TEXT
Query!
Linked study record
Query!
Health condition
Health condition(s) or problem(s) studied:
Breast Cancer
0
0
Query!
Condition category
Condition code
Cancer
0
0
0
0
Query!
Breast
Query!
Intervention/exposure
Study type
Interventional
Query!
Description of intervention(s) / exposure
Active comparator: T+OFS - Ovarian function suppression (OFS) by triptorelin (GnRH analogue) 3.75mg by im injection q28 days for 5 years plus tamoxifen 20mg orally daily for 5 years. Tamoxifen (T) begins after the completion of adjuvant chemotherapy if given, or approximately 6-8 weeks after the initiation of triptorelin. Bilateral oophorectomy or ovarian irradiation was allowed after at least 6 months of triptorelin.
Experimental: E+OFS - Ovarian function suppression (OFS) by triptorelin (GnRH analogue) 3.75mg by im injection q28 days for 5 years plus exemestane 25mg orally daily for 5 years. Exemestane (E) begins after the completion of adjuvant chemotherapy if given, or approximately 6-8 weeks after the initiation of triptorelin. Bilateral oophorectomy or ovarian irradiation was allowed after at least 6 months of triptorelin.
Query!
Comparator / control treatment
Query!
Control group
Query!
Outcomes
Primary outcome [1]
0
0
Disease-free Survival
Query!
Assessment method [1]
0
0
Estimated percentage of patients alive and disease-free at 5 years from randomization, where disease-free survival is defined as the time from randomization to the first appearance of one of the following: invasive breast cancer recurrence at local, regional, or distant site, invasive contralateral breast cancer, second (non-breast) invasive cancer, or death without cancer event; or censored at date of last follow up.
Query!
Timepoint [1]
0
0
5-year estimate reported at a median follow-up of 72 months
Query!
Secondary outcome [1]
0
0
Breast Cancer-free Interval
Query!
Assessment method [1]
0
0
Estimated percentage of patients alive and disease-free at 5 years from randomization, where breast cancer-free interval is defined as the time from randomization to the invasive breast cancer recurrence at local, regional, or distant site, or invasive contralateral breast cancer; or censored at date of last follow up.
Query!
Timepoint [1]
0
0
5-year estimate reported at a median follow-up of 72 months
Query!
Secondary outcome [2]
0
0
Distant Recurrence-free Interval
Query!
Assessment method [2]
0
0
Estimated percentage of patients alive and disease-free at 5 years from randomization, where distant recurrence-free interval is defined as the time from randomization to breast cancer recurrence at a distant site; or censored at date of last follow-up
Query!
Timepoint [2]
0
0
5-year estimates reported at a median follow-up of 72 months
Query!
Secondary outcome [3]
0
0
Overall Survival
Query!
Assessment method [3]
0
0
Estimated percentage of patients alive at 8 years from randomization, where overall survival is defined as the time from randomization to death from any cause; or censored at date last known alive.
Query!
Timepoint [3]
0
0
8-year estimates, reported at a median follow-up of 9 years
Query!
Eligibility
Key inclusion criteria
DISEASE CHARACTERISTICS:
* Histologically confirmed breast cancer
* Completely resected disease
* No clinically detectable residual loco-regional axillary disease
* Prior surgery for primary breast cancer of 1 of the following types:
* Total mastectomy with or without adjuvant radiotherapy
* Breast-conserving procedure (e.g., lumpectomy, quadrantectomy, or partial mastectomy with margins negative* for invasive disease and ductal carcinoma in situ) with planned radiotherapy NOTE: *If all other margins are clear a positive posterior (deep) margin is permitted, provided the excision was performed down to the pectoral fascia and all tumor has been removed OR a positive anterior (superficial; abutting skin) margin is allowed provided all tumor was removed
* Tumor confined to the breast and axillary nodes
* Tumor detected in internal mammary chain nodes by sentinel node procedure and is not enlarged is allowed
* Axillary lymph node dissection or a negative axillary sentinel node biopsy required
* Patients with negative or microscopically positive axillary sentinel nodes are eligible
* Positive sentinel nodes must have either axillary dissection or radiation of axillary nodes
* No distant metastases
* No locally advanced inoperable breast cancer, including any of the following:
* Inflammatory breast cancer
* Supraclavicular node involvement
* Enlarged internal mammary nodes (unless pathologically negative)
* Bilateral synchronous invasive breast cancer allowed if disease meets all other eligibility criteria
* No prior ipsilateral or contralateral invasive breast cancer
* Hormone receptor status:
* Estrogen and/or progesterone receptor positive
* At least 10% of the tumor cells positive by immunohistochemistry
* If > 1 breast tumor, each tumor must be hormone receptor positive
PATIENT CHARACTERISTICS:
Age
* Premenopausal
Sex
* Female
Menopausal status
* Premenopausal
* Estradiol in the premenopausal range after prior surgery OR meets the following criteria:
* Menstruating regularly for the past 6 months
* Has not used any form of hormonal treatment (including hormonal contraception) within the past 6 months
Performance status
* Not specified
Life expectancy
* Not specified
Hematopoietic
* Not specified
Hepatic
* No systemic hepatic disease that would preclude prolonged follow-up
Renal
* No systemic renal disease that would preclude prolonged follow-up
Cardiovascular
* No systemic cardiovascular disease that would preclude prolonged follow-up
* No prior thrombosis (e.g., deep vein thrombosis) and/or embolism unless patient is medically suitable
Pulmonary
* No systemic pulmonary disease that would preclude prolonged follow-up
Other
* Not pregnant or nursing
* Fertile patients must use effective nonhormonal contraception
* No history of noncompliance to medical regimens
* No other nonmalignant systemic disease that would preclude prolonged follow-up
* No other malignancy within the past 5 years except adequately treated basal cell or squamous cell skin cancer, nonbreast carcinoma in situ, contralateral or ipsilateral carcinoma in situ of the breast, or other nonrecurrent invasive nonbreast malignancy, including any of the following:
* Stage I papillary thyroid cancer
* Stage IA carcinoma of the cervix
* Stage IA or B endometrioid endometrial cancer
* Borderline or stage I ovarian cancer
* No psychiatric, addictive, or other disorder that would preclude study compliance
PRIOR CONCURRENT THERAPY:
Biologic therapy
* Prior or concurrent neoadjuvant or adjuvant trastuzumab allowed
Chemotherapy
* No prior neoadjuvant or adjuvant chemotherapy
Endocrine therapy
* No prior tamoxifen, other selective estrogen-receptor modulators (SERMs) (e.g., raloxifene), or hormone replacement therapy for more than 1 year before breast cancer diagnosis
* No prior neoadjuvant or adjuvant endocrine therapy since diagnosis of breast cancer
* No concurrent oral or transdermal hormonal therapy
* No other concurrent estrogen, progesterone, or androgens
* No other concurrent aromatase inhibitors
* No concurrent oral or other hormonal contraceptives (i.e., implants or depot injections)
Radiotherapy
* See Disease Characteristics
* No prior ovarian radiotherapy
Surgery
* See Disease Characteristics
* No prior bilateral oophorectomy
Other
* No concurrent bisphosphonates, except in the following cases:
* Bone density is at least 1.5 standard deviations below the young adult normal mean
* Participation in a randomized clinical study testing bisphosphonates in the adjuvant breast cancer setting
* No other concurrent investigational agents
Query!
Minimum age
18
Years
Query!
Query!
Maximum age
65
Years
Query!
Query!
Sex
Females
Query!
Can healthy volunteers participate?
No
Query!
Key exclusion criteria
Query!
Study design
Purpose of the study
Treatment
Query!
Allocation to intervention
Randomised controlled trial
Query!
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Query!
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Query!
Masking / blinding
Open (masking not used)
Query!
Who is / are masked / blinded?
Query!
Query!
Query!
Query!
Intervention assignment
Parallel
Query!
Other design features
Query!
Phase
Phase 3
Query!
Type of endpoint/s
Query!
Statistical methods / analysis
Query!
Recruitment
Recruitment status
Active, not recruiting
Query!
Data analysis
Query!
Reason for early stopping/withdrawal
Query!
Other reasons
Query!
Date of first participant enrolment
Anticipated
Query!
Actual
3/11/2003
Query!
Date of last participant enrolment
Anticipated
Query!
Actual
Query!
Date of last data collection
Anticipated
1/12/2025
Query!
Actual
Query!
Sample size
Target
Query!
Accrual to date
Query!
Final
2672
Query!
Recruitment in Australia
Recruitment state(s)
NSW,QLD,SA,TAS,VIC,WA
Query!
Recruitment hospital [1]
0
0
Cancer Therapy Centre at Campbelltown Hospital - Campbelltown
Query!
Recruitment hospital [2]
0
0
Coffs Harbour Health Campus - Coffs Harbour
Query!
Recruitment hospital [3]
0
0
Lismore Base Hospital - Lismore
Query!
Recruitment hospital [4]
0
0
Cancer Therapy Centre at Liverpool Hospital - Liverpool
Query!
Recruitment hospital [5]
0
0
Tamworth Base Hospital - Tamworth
Query!
Recruitment hospital [6]
0
0
Manning Base Hospital - Taree
Query!
Recruitment hospital [7]
0
0
Tweed Heads Hospital - Tweed Heads
Query!
Recruitment hospital [8]
0
0
Newcastle Mater Misericordiae Hospital - Waratah
Query!
Recruitment hospital [9]
0
0
Royal Brisbane and Women's Hospital - Brisbane
Query!
Recruitment hospital [10]
0
0
Flinders Medical Centre - Bedford Park
Query!
Recruitment hospital [11]
0
0
Royal Hobart Hospital - Hobart
Query!
Recruitment hospital [12]
0
0
Launceston General Hospital - Launceston
Query!
Recruitment hospital [13]
0
0
Box Hill Hospital - Box Hill
Query!
Recruitment hospital [14]
0
0
Breast Unit Mercy Private - East Melbourne
Query!
Recruitment hospital [15]
0
0
Peter MacCallum Cancer Centre - East Melbourne
Query!
Recruitment hospital [16]
0
0
St. Vincent's Hospital - Melbourne - Fitzroy
Query!
Recruitment hospital [17]
0
0
Austin Hospital - Heidelberg
Query!
Recruitment hospital [18]
0
0
Alfred Hospital - Melbourne
Query!
Recruitment hospital [19]
0
0
Maroondah Hospital - Ringwood East
Query!
Recruitment hospital [20]
0
0
Royal Perth Hospital - Perth
Query!
Recruitment postcode(s) [1]
0
0
2560 - Campbelltown
Query!
Recruitment postcode(s) [2]
0
0
2450 - Coffs Harbour
Query!
Recruitment postcode(s) [3]
0
0
2480 - Lismore
Query!
Recruitment postcode(s) [4]
0
0
2170 - Liverpool
Query!
Recruitment postcode(s) [5]
0
0
2340 - Tamworth
Query!
Recruitment postcode(s) [6]
0
0
2430 - Taree
Query!
Recruitment postcode(s) [7]
0
0
2485 - Tweed Heads
Query!
Recruitment postcode(s) [8]
0
0
2298 - Waratah
Query!
Recruitment postcode(s) [9]
0
0
4029 - Brisbane
Query!
Recruitment postcode(s) [10]
0
0
5042 - Bedford Park
Query!
Recruitment postcode(s) [11]
0
0
7000 - Hobart
Query!
Recruitment postcode(s) [12]
0
0
7250 - Launceston
Query!
Recruitment postcode(s) [13]
0
0
3128 - Box Hill
Query!
Recruitment postcode(s) [14]
0
0
3002 - East Melbourne
Query!
Recruitment postcode(s) [15]
0
0
3065 - Fitzroy
Query!
Recruitment postcode(s) [16]
0
0
3084 - Heidelberg
Query!
Recruitment postcode(s) [17]
0
0
3004 - Melbourne
Query!
Recruitment postcode(s) [18]
0
0
3135 - Ringwood East
Query!
Recruitment postcode(s) [19]
0
0
6000 - Perth
Query!
Recruitment outside Australia
Country [1]
0
0
United States of America
Query!
State/province [1]
0
0
California
Query!
Country [2]
0
0
United States of America
Query!
State/province [2]
0
0
Colorado
Query!
Country [3]
0
0
United States of America
Query!
State/province [3]
0
0
Connecticut
Query!
Country [4]
0
0
United States of America
Query!
State/province [4]
0
0
District of Columbia
Query!
Country [5]
0
0
United States of America
Query!
State/province [5]
0
0
Florida
Query!
Country [6]
0
0
United States of America
Query!
State/province [6]
0
0
Georgia
Query!
Country [7]
0
0
United States of America
Query!
State/province [7]
0
0
Idaho
Query!
Country [8]
0
0
United States of America
Query!
State/province [8]
0
0
Illinois
Query!
Country [9]
0
0
United States of America
Query!
State/province [9]
0
0
Indiana
Query!
Country [10]
0
0
United States of America
Query!
State/province [10]
0
0
Iowa
Query!
Country [11]
0
0
United States of America
Query!
State/province [11]
0
0
Kansas
Query!
Country [12]
0
0
United States of America
Query!
State/province [12]
0
0
Maryland
Query!
Country [13]
0
0
United States of America
Query!
State/province [13]
0
0
Massachusetts
Query!
Country [14]
0
0
United States of America
Query!
State/province [14]
0
0
Michigan
Query!
Country [15]
0
0
United States of America
Query!
State/province [15]
0
0
Minnesota
Query!
Country [16]
0
0
United States of America
Query!
State/province [16]
0
0
Missouri
Query!
Country [17]
0
0
United States of America
Query!
State/province [17]
0
0
Nebraska
Query!
Country [18]
0
0
United States of America
Query!
State/province [18]
0
0
New Jersey
Query!
Country [19]
0
0
United States of America
Query!
State/province [19]
0
0
New York
Query!
Country [20]
0
0
United States of America
Query!
State/province [20]
0
0
North Carolina
Query!
Country [21]
0
0
United States of America
Query!
State/province [21]
0
0
Ohio
Query!
Country [22]
0
0
United States of America
Query!
State/province [22]
0
0
Pennsylvania
Query!
Country [23]
0
0
United States of America
Query!
State/province [23]
0
0
South Carolina
Query!
Country [24]
0
0
United States of America
Query!
State/province [24]
0
0
South Dakota
Query!
Country [25]
0
0
United States of America
Query!
State/province [25]
0
0
Tennessee
Query!
Country [26]
0
0
United States of America
Query!
State/province [26]
0
0
Texas
Query!
Country [27]
0
0
United States of America
Query!
State/province [27]
0
0
Vermont
Query!
Country [28]
0
0
United States of America
Query!
State/province [28]
0
0
Washington
Query!
Country [29]
0
0
United States of America
Query!
State/province [29]
0
0
West Virginia
Query!
Country [30]
0
0
United States of America
Query!
State/province [30]
0
0
Wisconsin
Query!
Country [31]
0
0
Belgium
Query!
State/province [31]
0
0
Brussels
Query!
Country [32]
0
0
Belgium
Query!
State/province [32]
0
0
Huy
Query!
Country [33]
0
0
Belgium
Query!
State/province [33]
0
0
Leuven
Query!
Country [34]
0
0
Belgium
Query!
State/province [34]
0
0
Liege
Query!
Country [35]
0
0
Belgium
Query!
State/province [35]
0
0
Verviers
Query!
Country [36]
0
0
Brazil
Query!
State/province [36]
0
0
Rio Grande Do Sul
Query!
Country [37]
0
0
Canada
Query!
State/province [37]
0
0
Alberta
Query!
Country [38]
0
0
Canada
Query!
State/province [38]
0
0
New Brunswick
Query!
Country [39]
0
0
Canada
Query!
State/province [39]
0
0
Ontario
Query!
Country [40]
0
0
Canada
Query!
State/province [40]
0
0
Quebec
Query!
Country [41]
0
0
Canada
Query!
State/province [41]
0
0
Saskatchewan
Query!
Country [42]
0
0
Egypt
Query!
State/province [42]
0
0
Cairo
Query!
Country [43]
0
0
Germany
Query!
State/province [43]
0
0
Baden-Baden
Query!
Country [44]
0
0
Germany
Query!
State/province [44]
0
0
Deggendorf
Query!
Country [45]
0
0
Germany
Query!
State/province [45]
0
0
Erlangen
Query!
Country [46]
0
0
Germany
Query!
State/province [46]
0
0
Frankfurt
Query!
Country [47]
0
0
Germany
Query!
State/province [47]
0
0
Göttingen
Query!
Country [48]
0
0
Germany
Query!
State/province [48]
0
0
Karlsruhe
Query!
Country [49]
0
0
Germany
Query!
State/province [49]
0
0
Luebeck
Query!
Country [50]
0
0
Germany
Query!
State/province [50]
0
0
Mainz
Query!
Country [51]
0
0
Germany
Query!
State/province [51]
0
0
Mannheim
Query!
Country [52]
0
0
Germany
Query!
State/province [52]
0
0
Mutlangen
Query!
Country [53]
0
0
Germany
Query!
State/province [53]
0
0
Nuremberg
Query!
Country [54]
0
0
Germany
Query!
State/province [54]
0
0
Regensburg
Query!
Country [55]
0
0
Germany
Query!
State/province [55]
0
0
Rodewisch
Query!
Country [56]
0
0
Germany
Query!
State/province [56]
0
0
Rosenheim
Query!
Country [57]
0
0
Germany
Query!
State/province [57]
0
0
Tuttlingen
Query!
Country [58]
0
0
Hungary
Query!
State/province [58]
0
0
Budapest
Query!
Country [59]
0
0
India
Query!
State/province [59]
0
0
Mumbai
Query!
Country [60]
0
0
Italy
Query!
State/province [60]
0
0
Aviano
Query!
Country [61]
0
0
Italy
Query!
State/province [61]
0
0
Bergamo
Query!
Country [62]
0
0
Italy
Query!
State/province [62]
0
0
Bolzano
Query!
Country [63]
0
0
Italy
Query!
State/province [63]
0
0
Brescia
Query!
Country [64]
0
0
Italy
Query!
State/province [64]
0
0
Carpi
Query!
Country [65]
0
0
Italy
Query!
State/province [65]
0
0
Milan
Query!
Country [66]
0
0
Italy
Query!
State/province [66]
0
0
Pavia
Query!
Country [67]
0
0
Italy
Query!
State/province [67]
0
0
Prato
Query!
Country [68]
0
0
Italy
Query!
State/province [68]
0
0
Rimini
Query!
Country [69]
0
0
Italy
Query!
State/province [69]
0
0
Rozzano
Query!
Country [70]
0
0
Italy
Query!
State/province [70]
0
0
Udine
Query!
Country [71]
0
0
Italy
Query!
State/province [71]
0
0
Varese
Query!
Country [72]
0
0
New Zealand
Query!
State/province [72]
0
0
Hamilton
Query!
Country [73]
0
0
Peru
Query!
State/province [73]
0
0
Lima
Query!
Country [74]
0
0
Slovenia
Query!
State/province [74]
0
0
Ljubljana
Query!
Country [75]
0
0
South Africa
Query!
State/province [75]
0
0
Johannesburg
Query!
Country [76]
0
0
Sweden
Query!
State/province [76]
0
0
Gothenburg
Query!
Country [77]
0
0
Sweden
Query!
State/province [77]
0
0
Linkoping
Query!
Country [78]
0
0
Sweden
Query!
State/province [78]
0
0
Skovde
Query!
Country [79]
0
0
Switzerland
Query!
State/province [79]
0
0
Basel
Query!
Country [80]
0
0
Switzerland
Query!
State/province [80]
0
0
Bellinzona
Query!
Country [81]
0
0
Switzerland
Query!
State/province [81]
0
0
Bern
Query!
Country [82]
0
0
Switzerland
Query!
State/province [82]
0
0
Chur
Query!
Country [83]
0
0
Switzerland
Query!
State/province [83]
0
0
Lausanne
Query!
Country [84]
0
0
Switzerland
Query!
State/province [84]
0
0
Locarno
Query!
Country [85]
0
0
Switzerland
Query!
State/province [85]
0
0
Lugano
Query!
Country [86]
0
0
Switzerland
Query!
State/province [86]
0
0
Mendrisio
Query!
Country [87]
0
0
Switzerland
Query!
State/province [87]
0
0
St. Gallen
Query!
Country [88]
0
0
Switzerland
Query!
State/province [88]
0
0
Thun
Query!
Country [89]
0
0
Switzerland
Query!
State/province [89]
0
0
Zurich
Query!
Country [90]
0
0
United Kingdom
Query!
State/province [90]
0
0
England
Query!
Funding & Sponsors
Primary sponsor type
Other
Query!
Name
ETOP IBCSG Partners Foundation
Query!
Address
Query!
Country
Query!
Other collaborator category [1]
0
0
Government body
Query!
Name [1]
0
0
National Cancer Institute (NCI)
Query!
Address [1]
0
0
Query!
Country [1]
0
0
Query!
Other collaborator category [2]
0
0
Other
Query!
Name [2]
0
0
Breast International Group
Query!
Address [2]
0
0
Query!
Country [2]
0
0
Query!
Ethics approval
Ethics application status
Query!
Summary
Brief summary
RATIONALE: Estrogen can stimulate the growth of breast cancer cells. Hormone therapy using triptorelin, exemestane, and tamoxifen may fight breast cancer by blocking the use of estrogen. It is not yet known whether giving triptorelin together with exemestane is more effective than triptorelin and tamoxifen in treating hormone-responsive breast cancer. PURPOSE: This randomized phase III trial is studying triptorelin and exemestane to see how well they work compared to triptorelin and tamoxifen in treating premenopausal women with hormone-responsive breast cancer.
Query!
Trial website
https://clinicaltrials.gov/study/NCT00066703
Query!
Trial related presentations / publications
Francis P, Fleming G, Nasi ML, et al.: Tailored treatment investigations for premenopausal women with endocrine responsive (ER+ and/or PGR+) breast cancer: the SOFT, TEXT, and PERCHE trials. [Abstract] The Breast 12 (Suppl 1): A-P104, S44, 2003. Regan MM, Pagani O, Walley B, Torrisi R, Perez EA, Francis P, Fleming GF, Price KN, Thurlimann B, Maibach R, Castiglione-Gertsch M, Coates AS, Goldhirsch A, Gelber RD; SOFT/TEXT/PERCHE Steering Committee and the International Breast Cancer Study Group. Premenopausal endocrine-responsive early breast cancer: who receives chemotherapy? Ann Oncol. 2008 Jul;19(7):1231-1241. doi: 10.1093/annonc/mdn037. Epub 2008 Mar 5. Rabaglio M, Ruepp B; Soft/Text/Perche Steering Committee. Death due to liver failure during endocrine therapy for premenopausal breast cancer. Acta Oncol. 2010 Aug;49(6):874-6. doi: 10.3109/0284186X.2010.484813. No abstract available. Regan MM, Pagani O, Fleming GF, Walley BA, Price KN, Rabaglio M, Maibach R, Ruepp B, Coates AS, Goldhirsch A, Colleoni M, Gelber RD, Francis PA; International Breast Cancer Study; GroupSOFT and TEXT Investigators. Adjuvant treatment of premenopausal women with endocrine-responsive early breast cancer: design of the TEXT and SOFT trials. Breast. 2013 Dec;22(6):1094-100. doi: 10.1016/j.breast.2013.08.009. Epub 2013 Oct 2. Pagani O, Regan MM, Walley BA, Fleming GF, Colleoni M, Lang I, Gomez HL, Tondini C, Burstein HJ, Perez EA, Ciruelos E, Stearns V, Bonnefoi HR, Martino S, Geyer CE Jr, Pinotti G, Puglisi F, Crivellari D, Ruhstaller T, Winer EP, Rabaglio-Poretti M, Maibach R, Ruepp B, Giobbie-Hurder A, Price KN, Bernhard J, Luo W, Ribi K, Viale G, Coates AS, Gelber RD, Goldhirsch A, Francis PA; TEXT and SOFT Investigators; International Breast Cancer Study Group. Adjuvant exemestane with ovarian suppression in premenopausal breast cancer. N Engl J Med. 2014 Jul 10;371(2):107-18. doi: 10.1056/NEJMoa1404037. Epub 2014 Jun 1. Pagani O, Walley BA, Fleming GF, Colleoni M, Lang I, Gomez HL, Tondini C, Burstein HJ, Goetz MP, Ciruelos EM, Stearns V, Bonnefoi HR, Martino S, Geyer CE Jr, Chini C, Puglisi F, Spazzapan S, Ruhstaller T, Winer EP, Ruepp B, Loi S, Coates AS, Gelber RD, Goldhirsch A, Regan MM, Francis PA; SOFT and TEXT Investigators and the International Breast Cancer Study Group (a division of ETOP IBCSG Partners Foundation). Adjuvant Exemestane With Ovarian Suppression in Premenopausal Breast Cancer: Long-Term Follow-Up of the Combined TEXT and SOFT Trials. J Clin Oncol. 2023 Mar 1;41(7):1376-1382. doi: 10.1200/JCO.22.01064. Epub 2022 Dec 15. Pagani O, Francis PA, Fleming GF, Walley BA, Viale G, Colleoni M, Lang I, Gomez HL, Tondini C, Pinotti G, Di Leo A, Coates AS, Goldhirsch A, Gelber RD, Regan MM; SOFT and TEXT Investigators and International Breast Cancer Study Group. Absolute Improvements in Freedom From Distant Recurrence to Tailor Adjuvant Endocrine Therapies for Premenopausal Women: Results From TEXT and SOFT. J Clin Oncol. 2020 Apr 20;38(12):1293-1303. doi: 10.1200/JCO.18.01967. Epub 2019 Oct 16. Francis PA, Pagani O, Fleming GF, Walley BA, Colleoni M, Lang I, Gomez HL, Tondini C, Ciruelos E, Burstein HJ, Bonnefoi HR, Bellet M, Martino S, Geyer CE Jr, Goetz MP, Stearns V, Pinotti G, Puglisi F, Spazzapan S, Climent MA, Pavesi L, Ruhstaller T, Davidson NE, Coleman R, Debled M, Buchholz S, Ingle JN, Winer EP, Maibach R, Rabaglio-Poretti M, Ruepp B, Di Leo A, Coates AS, Gelber RD, Goldhirsch A, Regan MM; SOFT and TEXT Investigators and the International Breast Cancer Study Group. Tailoring Adjuvant Endocrine Therapy for Premenopausal Breast Cancer. N Engl J Med. 2018 Jul 12;379(2):122-137. doi: 10.1056/NEJMoa1803164. Epub 2018 Jun 4. Regan MM, Walley BA, Francis PA, Fleming GF, Lang I, Gomez HL, Colleoni M, Tondini C, Pinotti G, Salim M, Spazzapan S, Parmar V, Ruhstaller T, Abdi EA, Gelber RD, Coates AS, Goldhirsch A, Pagani O. Concurrent and sequential initiation of ovarian function suppression with chemotherapy in premenopausal women with endocrine-responsive early breast cancer: an exploratory analysis of TEXT and SOFT. Ann Oncol. 2017 Sep 1;28(9):2225-2232. doi: 10.1093/annonc/mdx285. Johansson H, Gray KP, Pagani O, Regan MM, Viale G, Aristarco V, Macis D, Puccio A, Roux S, Maibach R, Colleoni M, Rabaglio M, Price KN, Coates AS, Gelber RD, Goldhirsch A, Kammler R, Bonanni B, Walley BA; the TEXT principal investigators. Impact of CYP19A1 and ESR1 variants on early-onset side effects during combined endocrine therapy in the TEXT trial. Breast Cancer Res. 2016 Nov 8;18(1):110. doi: 10.1186/s13058-016-0771-8. Regan MM, Francis PA, Pagani O, Fleming GF, Walley BA, Viale G, Colleoni M, Lang I, Gomez HL, Tondini C, Pinotti G, Price KN, Coates AS, Goldhirsch A, Gelber RD. Absolute Benefit of Adjuvant Endocrine Therapies for Premenopausal Women With Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Early Breast Cancer: TEXT and SOFT Trials. J Clin Oncol. 2016 Jul 1;34(19):2221-31. doi: 10.1200/JCO.2015.64.3171. Epub 2016 Apr 4. Bernhard J, Luo W, Ribi K, Colleoni M, Burstein HJ, Tondini C, Pinotti G, Spazzapan S, Ruhstaller T, Puglisi F, Pavesi L, Parmar V, Regan MM, Pagani O, Fleming GF, Francis PA, Price KN, Coates AS, Gelber RD, Goldhirsch A, Walley BA. Patient-reported outcomes with adjuvant exemestane versus tamoxifen in premenopausal women with early breast cancer undergoing ovarian suppression (TEXT and SOFT): a combined analysis of two phase 3 randomised trials. Lancet Oncol. 2015 Jul;16(7):848-58. doi: 10.1016/S1470-2045(15)00049-2. Epub 2015 Jun 16.
Query!
Public notes
Query!
Contacts
Principal investigator
Name
0
0
Olivia Pagani, MD
Query!
Address
0
0
Oncology Institute of Southern Switzerland
Query!
Country
0
0
Query!
Phone
0
0
Query!
Fax
0
0
Query!
Email
0
0
Query!
Contact person for public queries
Name
0
0
Query!
Address
0
0
Query!
Country
0
0
Query!
Phone
0
0
Query!
Fax
0
0
Query!
Email
0
0
Query!
Contact person for scientific queries
No information has been provided regarding IPD availability
What supporting documents are/will be available?
No Supporting Document Provided
Results publications and other study-related documents
Type
Citations or Other Details
Journal
Pagani O, Regan MM, Walley BA, Fleming GF, Colleon...
[
More Details
]
Journal
Pagani O, Walley BA, Fleming GF, Colleoni M, Lang ...
[
More Details
]
Results are available at
https://clinicaltrials.gov/study/NCT00066703
Download to PDF